CQN-CA-NAX
Please replace the logo in the release dated January 13, 2021 with the accompanying corrected logo.
The release reads:
NAX LAUNCHES AS FIRST PLATFORM TO CREATE CORPORATE ASSET-BACKED PRODUCTS, VENTURES AND SECURITIES
- Company founded by Jeff Schumacher
- Company already valued at over $300m USD
New Asset Exchange (NAX), a company that brings liquidity to corporate assets, has formally launched today after two and a half years in stealth development. It has established a new model for launching corporate asset-backed products, ventures and securities. NAX is founded by serial entrepreneur Jeff Schumacher.
NAX combines the software and the method to identify, build, launch and scale asset-backed products, ventures and securitized assets for institutional trading. NAX has secured $65m USD to date in investment from 12 institutional, family office and corporate investors across North America, Europe and Asia, valuing the company at over $300m USD. It launches with a global team based in North America and Europe.
NAX has developed software for digital, micro and platform services, as well as cloud commerce that can be utilized to rapidly market test fully compliant products, tradable securities and marketplaces. The firm will be announcing a series of milestones in the coming months to match its ambitious growth plans.
NAX is already working with leading global businesses in multiple industries including energy, healthcare and consumer goods to launch corporate asset-backed products, and is supported by operating partners from global leaders in trading, banking and underwriting to deliver the requisite infrastructure.
NAX CEO and founder Jeff Schumacher, previously founded and scaled BCG Digital Ventures, with the company becoming one of the largest foundries in the world, creating more than 100 businesses and growing to over 1,000 employees in less than six years. He also founded Axon Advisory Partners, before selling it to Booz & Co., creating Booz Digital, which was then acquired by PwC. Schumacher was previously a Partner at McKinsey, and also EVP, CMO and CSO at Sports Authority, a Leonard Green Partners portfolio company.
Jeff Schumacher, CEO and Founder, NAX said: “We are building upon a decade of learnings from working with the world's leading financial exchanges and institutions. With NAX, we are bringing financial innovation across sectors to create value in markets that otherwise would not exist.”
Since its inception, NAX has attracted several high-profile business figures to its Board, including Frank Strauß, former Global CEO of Private and Commercial Banking at Deutsche Bank, and Heiner Leisten, Leisten & Cie. Family Office CEO and previously Senior Partner at BCG, among others.
Frank Strauß, Independent Board Member, NAX said: “In today’s world, financial innovation is the bedrock upon which successful ventures are created. Jeff’s vision for NAX is what attracted me to supporting the company in applying financial innovation to corporate assets and ultimately unlocking significant value from those assets.”
Francisco Arcilla, Partner, TNF Investments, which led the latest NAX fundraising round, said: “As an international investment firm that prides itself on being a catalyst for innovation and industry disruption, we were instantly captivated by NAX and its disruptive approach to asset creation and value generation. We were very excited to lead the latest round of funding for NAX, and we are equally enthusiastic about the prospect of the many ventures and further investment opportunities that NAX will create.“
NAX operates from its headquarters in Manhattan Beach, CA for North America and Paris, France for Europe, with further locations in Palo Alto, New York, London, and Frankfurt. In 2021, it will be expanding to Singapore, Tokyo and Sydney.
About NAX
NAX is a platform to create asset-backed products, ventures and securities for the world's leading institutions. We co-lead the commercialization of these initiatives with our partners.
For more information, visit http://www.naxgrp.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom